Size and Treatment Outcomes of HR+, HER2- Early Breast Cancer Population With High Risk of Recurrence: A Real-World Cohort Study With Danish Breast Cancer Cooperative Group Registry Data

Size and Treatment Outcomes of HR+, HER2- Early Breast Cancer Population With High Risk of Recurrence: A Real-World Cohort Study With Danish Breast Cancer Cooperative Group Registry Data

# Background While the prognosis is generally good for hormone receptor–positive (HR+), human epidermal growth factor–negative (HER2–) early breast cancer (EBC) patients, up to 30% of patients with high-risk clinical and/or pathologic features experience recurrence. # Objectives This retrospective...

Full description

Saved in:
Bibliographic Details
Main Authors: Heidi Loponen, Juha Mehtälä, Laila Mehkri, Astrid Torstensson, Anna Emde, Tero Ylisaukko-oja, Walid Fakhouri
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2025-06-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/001c.137277
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://doi.org/10.36469/001c.137277

Similar Items